CNS/Neurology

Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, Floricel F, Lorenzen J, Bonfitto F, Kalilani L, Loesch C, Luscombe G, Perez-Gutthann S, Mottet I, Foskett N. Incidence of acute renal failure in patients using Levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf. 2022 Jul;45(7):781-90. doi: 10.1007/s40264-022-01193-0


Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Published Erratum - Correction to:  Staging disease severity using the Alzheimer's Disease Composite Score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Jun;11(2):915-27. doi: 10.1007/s40120-022-00340-0


Abstract not available at this time.

Layton JB, Forns Guzman J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Mortality in patients with Parkinson's disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study. Drug Saf. 2023 Feb 1;46(2):195-208. doi: 10.1007/s40264-022-01260-6


INTRODUCTION: Pimavanserin is approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). Objectives: We evaluated mortality in patients with PDP after initiation of pimavanserin or comparator atypical antipsychotics, overall, over time, and across subgroups.

Ainsworth C, Higuchi K, Simou E, Guyot P, Araujo L, Greene N. Relative differences in brain volume loss with teriflunomide vs other disease-modifying therapies in relapsing multiple sclerosis: a systematic review and network meta-analysis. Poster presented at the AMCP Nexus 2022; October 11, 2022. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2022 Oct; 28(10-a):S73-4. Previously presented at the ACTRIMS Forum 2022.


Layton JB, McQuay L, Forns J, Danysh HE, Dempsey C, Anthony MS, Turner ME. Risk of mortality associated with pimavanserin compared with atypical antipsychotics in patients with Parkinson's disease–related psychosis. Presented at the 2022 American Society of Clinical Psychopharmacology (ASCP); May 31, 2022. Scottsdale, AZ.


Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Billet JP. Impact of Huntington's disease on driving: a review of driving simulator measures and association with clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).


Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Petrillo Billet J. Driving outcomes in mild cognitive impairment/Alzheimer's disease -  a review of association between driving simulator measures and clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).


Bradley Layton J, McQuay L, Forns J, Danysh H, Dempsey C, Anthony MS, Turner ME. Risk of mortality associated with pimavanserin compared with atypical antipsychotics in patients with Parkinson's disease–related psychosis. Presented at the 2022 ICPE Conference; August 27, 2022. Copenhagen, Denmark. Previously presented at the 2022 American Society of Clinical Psychopharmacology (ASCP).


Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Staging disease severity using the Alzheimer's disease composite score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Mar;11(1):413-34. doi: 10.1007/s40120-022-00326-y


Saidha S, Bell J, Harold SE, Marcano Belisario JS, Hawe E, Shao Q, Wyse K, Maiese EM. A systematic literature review of immunoglobulin levels among B-cell–depleting therapies and risk of infections in relapsing multiple sclerosis. Poster presented at the 2022 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting; June 1, 2022. National Harbor, MD.


Subscribe to CNS/Neurology

How Can We Help You?